Efficacy of Combined Amlodipine/Terazosin Therapy in Male Hypertensive Patients With Lower Urinary Tract Symptoms: A Randomized, Double-blind Clinical Trial

Urology

Volumn 74, Issue 1, 2009, Pages 130-136

  Liu, Haipeng ^a   Liu, Ping ^b   Mao, Guangyun ^b,c   Chen, Guangliang ^b   Wang, Binyan ^b   Qin, Xianhui ^b   Na, Yanqun ^d   Liu, Zeyuan ^e   Wang, Xiaobin ^f   Xu, Xiping ^a,b,g  

^a UNIVERSITY OF SCIENCE AND TECHNOLOGY OF CHINA   (China)

^b ANHUI MEDICAL UNIVERSITY   (China)

^c WENZHOU MEDICAL UNIVERSITY   (China)

^d PEKING UNIVERSITY   (China)

^e BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^f CHILDREN'S MEMORIAL HOSPITAL   (United States)

^g UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; TERAZOSIN;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CHINESE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; HEADACHE; HEART PALPITATION; HUMAN; HYPERTENSION; LOW DRUG DOSE; LOWER URINARY TRACT SYMPTOM; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; NAUSEA; OUTCOME ASSESSMENT; OVERACTIVE BLADDER; PERIPHERAL EDEMA; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT RESPONSE;

ADRENERGIC ALPHA-ANTAGONISTS; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PRAZOSIN; PROSTATISM;

EID: 67649224437     PISSN: 00904295     EISSN: 15279995     Source Type: Journal    
DOI: 10.1016/j.urology.2008.11.051     Document Type: Article

References (30)

1. Wong S.Y., Woo J., Hong A., et al. Risk factors for lower urinary tract symptoms in southern Chinese men. Urology 68 (2006) 1009-1014
2. Gu D., Gupta A., Muntner P., et al. Prevalence of cardiovascular disease risk factor clustering among the adult population of China: results from the international collaborative study of cardiovascular disease in Asia (inter Asia). Circulation 112 (2005) 658-665
3. Rosen R., Altwein J., Boyle P., et al. Lower urinary tract symptoms and male sexual dysfunction: the Multinational Survey of the Aging Male (MSAM-7). Eur Urol 44 (2003) 637-649
4. Parsons J.K. Modifiable risk factors for benign prostatic hyperplasia and lower urinary tract symptoms: new approaches to old problems. J Urol 178 (2007) 395-401
5. Rohrmann S., Smit E., Giovannucci E., et al. Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES III). Int J Obes 29 (2005) 310-316
6. Joseph M.A., Harlow S.D., Wei J.T., et al. Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. Am J Epidemiol 157 (2003) 906-914
7. Lee J.Y., Kim H.W., Lee S.J., et al. Comparison of doxazosin with or without tolterodine in men with symptomatic bladder outlet obstruction and an overactive bladder. BJU Int 94 (2004) 817-820
8. Chapple C.R., and Roehrborn C.G. A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol 49 (2006) 651-659
9. American Urological Association. Management of BPH Clinical Guidelines, 2003. Updated 2006. http://www.auanet.org/guidelines/bph.cfm Accessed September 2008
10. European Association of Urology. EAU guidelines on benign prostatic hyperplasia, 2004. http://www.uroweb.org/fileadmin/user_upload/Guidelines/BPH.pdf Accessed September 2008
11. Thorpe A., and Neal D. Benign prostatic hyperplasia. Lancet 361 (2003) 1359-1367
12. Kaplan S.A., Roehrborn C.G., Rovner E.S., et al. Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA 296 (2006) 2319-2328
13. Yang Y., Zhao X.F., Li H.Z., et al. Efficacy and Safety of combined therapy with terazosin and tolteradine for patients with lower urinary tract symptoms associated with benign prostatic hyperplasia: a prospective study. Chin Med J (Engl) 5 (2007) 370-374
14. Andersson K.E. Pharmacology of lower urinary tract smooth muscles and penile erectile tissues. Pharmacol Rev 45 (1993) 253-308
15. Badawi J.K., Li H., Langbein S., et al. Inhibitory effects of l- and t-type calcium antagonists on contractions of human detrusor muscle. Eur J Clin Pharmacol 62 (2006) 347-354
16. Chinese Urological Association. CUA guidelines on managements of urinary diseases. http://www.cuan.cn/cnspro/WebDiseaseGuide.aspx Accessed September 2008
17. Titmarsh S., and Monk J.P. Terazosin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in essential hypertension. Drugs 33 (1987) 461-477
18. Wykretowicz A., Guzik P., and Wysocki H. Doxazosin in the current treatment of hypertension. Expert Opin Pharmacother 9 (2008) 625-633
19. Aso Y., and Homma Y. Clinical research criteria: response criteria for evaluating efficacy of treatments for benign prostatic hypertrophy. Br J Urol 76 suppl 1 (1995) 69-73
20. Xu X., Niu T., Christiani D.C., et al. Environmental and occupational determinants of blood pressure in rural communities in China. Ann Epidemiol 7 (1997) 95-106
21. Tsujii T. Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol 7 (2000) 199-205
22. Tanaka Y., Masumori N., Itoh N., et al. Urodynamic effects of terazosin treatment for Japanese patients with symptomatic benign prostatic hyperplasia. J Urol 167 (2002) 2492-2495
23. Peili G., Chen X., Li H., et al. Clinical study of domestic terazosin on benign prostatic hyperplasia [in Chinese]. Chin J Clin Pharmacol 16 (2000) 338-341
24. Hashitani H., Bramich N.J., and Hirst G.D. Mechanisms of excitatory neuromuscular transmission in the guinea-pig urinary bladder. J Physiol 524 (2000) 565-579
25. Teramoto N., Yunoki T., Ikawa S., et al. The involvement of l-type Ca(2+) channels in the relaxant effects of the ATP-sensitive K(+) channel opener ZD6169 on pig urethral smooth muscle. Br J Pharmacol 134 (2001) 1505-1515
26. Eckert R.E., Schreier U., Drescher P., et al. Regulation of prostatic smooth muscle contractility by intracellular second messengers: implications for the conservative treatment of benign prostatic hyperplasia. Urol Int 54 (1995) 6-21
27. The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, the National Heart, Lung, and Blood Institute, and the National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 42 (2003) 1206-1252
28. Guideline Committee, European Society of Hypertension, European Society of Cardiology Guidelines for the Management of Arterial Hypertension. J Hypertens 21 (2003) 1011-1053
29. Pool J.L. Combination antihypertensive therapy with terazosin and other antihypertensive agents: results of clinical trials. Am Heart J 122 (1991) 926-931
30. Nalbantgil S., Nalbantgil I., and Onder R. Clinically additive effect between doxazosin and Amlodipine in the treatment of essential hypertension. Am J Hypertens 13 (2000) 921-926